Pharmos Corporation is a biopharmaceutical company that discovers and develops novel therapeutics to treat a range of diseases of the nervous system, including disorders of the brain-gut axis, with a focus on pain/inflammation and autoimmune disorders. The Company’s lead product, dextofisopam, is being studied in a Phase 2b clinical trial in patients with irritable bowel syndrome (IBS). In a Phase 2a IBS study, dextofisopam demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033) and was very well tolerated. A second program in clinical development is Pharmos’ proprietary NanoEmulsion cream drug delivery system formulated with NSAID diclofenac (3%), which is being studied in a Phase 2a trial as a pain medication in patients with knee osteoarthritis. Additionally, the Company has solid expertise and proprietary know-how in the discovery and development of synthetic cannabinoid compounds, especially CB2 receptor-selective (CB2-selective) agonists. PRS-639,058, the leading CB2-selective agonist, has demonstrated promising preclinical data in neuropathic pain. Various other CB2-selective compounds from Pharmos' library are in preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders.

Recent Releases

Nov 19, 2008
Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream

Nov 13, 2008
Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter

more »

Events

May 19, 2008
Rodman & Renshaw 5th Annual Global Healthcare Conference

more »